NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · IEX Real-Time Price · USD
18.90
+0.14 (0.75%)
At close: Jul 19, 2024, 4:00 PM
18.96
+0.06 (0.32%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
NAMS Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for NAMS stock have an average target of 33.25, with a low estimate of 30 and a high estimate of 37. The average target predicts an increase of 75.93% from the current stock price of 18.90.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jun 7, 2024.
Analyst Ratings
The average analyst rating for NAMS stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Buy | 3 | 4 | 4 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Reiterates $31 | Buy | Reiterates | $31 | +64.02% | Jun 7, 2024 |
| TD Cowen | TD Cowen | Strong Buy Initiates n/a | Strong Buy | Initiates | n/a | n/a | May 15, 2024 |
| Scotiabank | Scotiabank | Buy Initiates $35 | Buy | Initiates | $35 | +85.19% | Mar 14, 2024 |
| Scotiabank | Scotiabank | Buy Initiates $35 | Buy | Initiates | $35 | +85.19% | Mar 13, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $25 → $31 | Buy | Maintains | $25 → $31 | +64.02% | Feb 29, 2024 |
Financial Forecast
Revenue This Year
62.00M
from 14.09M
Increased by 340.04%
Revenue Next Year
9.54M
from 62.00M
Decreased by -84.62%
EPS This Year
-0.86
from -2.15
EPS Next Year
-2.57
from -0.86
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 30.3M | 14.5M | 116.8M | 242.9M | 407.5M |
| Avg | 9.5M | 5.6M | 50.4M | 123.3M | 302.7M |
| Low | n/a | n/a | 16.3M | 33.0M | 98.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 115.4% | 51.9% | 1,999.0% | 382.3% | 230.4% |
| Avg | -32.3% | -41.6% | 804.8% | 144.9% | 145.5% |
| Low | - | - | 192.6% | -34.5% | -19.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.02 | -0.63 | -1.18 | -0.02 | 0.95 |
| Avg | -2.57 | -1.22 | -1.15 | -1.02 | 0.25 |
| Low | -2.79 | -1.76 | -1.10 | -1.79 | -1.54 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.